Physical Optics Corporation — Department of Defense SBIR Phase II: To address the CBD need for improved formulations to enhance the ease of use and bioavaila

Description

To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to advance development of a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed system is based on a new dry powder formulation and a novel design of an inhaler that uses mature components developed in-house. POC"s innovations in the nanocarrier (NC) construct and in the design of the inhaler make it possible to deliver a single dose with the MATEN during one deep and slow inspiration. The MATEN enhances the bioavailability for antisense therapeutics that is necessary for the prophylaxes and early treatment of warfighters against emerging bio-warfare threats. Its formulation is stable at ambient temperature, minimizes the potential for introducing immunogenic materials, reduces the bulk and complexity of dispensing, and directly addresses the requirements of the Transformational Medical Technologies Initiative (TMTI) program. In Phase I, POC demonstrated the feasibility of the MATEN by demonstrating product stability and establishing enhanced bioavailability in an animal model. In Phase II, POC will optimize candidate formulation for maximum bioavailability and conduct initial pharmacokinetic and pharmacodynamic studies in an animal model.